Timpani Cara A, Rybalka Emma
Institute for Health and Sport, Victoria University, Melbourne, VIC 8001, Australia.
Australian Institute for Musculoskeletal Science, St Albans, VIC 3021, Australia.
Pharmaceuticals (Basel). 2020 Dec 26;14(1):15. doi: 10.3390/ph14010015.
COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine is in the pipeline, there is urgency for therapeutic options to address the immune dysregulation, hyperinflammation and oxidative stress that can lead to death. Given the shared pathogenesis of severe cases of COVID-19 with aspects of multiple sclerosis and psoriasis, we propose dimethyl fumarate as a viable treatment option. Currently approved for multiple sclerosis and psoriasis, dimethyl fumarate is an immunomodulatory, anti-inflammatory and anti-oxidative drug that could be rapidly implemented into the clinic to calm the cytokine storm which drives severe COVID-19.
新型冠状病毒肺炎（COVID-19）已在全球迅速传播，因呼吸窘迫而住院的病例数众多。虽然疫苗正在研发中，但迫切需要有治疗方案来应对可能导致死亡的免疫失调、过度炎症反应和氧化应激。鉴于COVID-19重症病例与多发性硬化症和银屑病存在共同的发病机制，我们提出富马酸二甲酯作为一种可行的治疗选择。富马酸二甲酯目前已被批准用于治疗多发性硬化症和银屑病，它是一种免疫调节、抗炎和抗氧化药物，可迅速应用于临床，以平息引发重症COVID-19的细胞因子风暴。
